-
Mashup Score: 4Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study - 12 month(s) ago
During the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®, Dr. Mustafa Hyder from the National Cancer Institute presented the results of…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Insights on Eltrombopag With Tommy Alfaro Moya at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® - 1 year(s) ago
Dr. Shernan Holtan speaks with Tommy Alfaro Moya at the the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®, who answers the question: Does…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
Does Eltrombopag help poor graft function after allo-transplant? @tomam04 and @sghmd discussed at #Tandem24. 🎤 Watch the interview on Nucleus: https://t.co/r29Qh0UAMl #alloHCT https://t.co/uS5IHNSBoD
-
-
Mashup Score: 11GVHD Insights from Two-time Transplant Recipient, Becky Dame of The Leukemia and Lymphoma Society - 1 year(s) ago
Drs. Jennifer Holter, MD, and Taha Al-Juhaishi, MD interview Becky Dame of The Leukemia and Lymphoma Society (LLS). Becky is a two-time transplant recipient and has personally battled GVHD….
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
At #Tandem24, @ouholter & @Taha_CancerDoc interviewed Becky Dame of @LLSusa. Becky is a 2x transplant recipient & has battled #GVHD. In this video, she shares her thoughts on the #GVHDAlliance & more. 🎤 View the interview on Nucleus: https://t.co/FvrnQm06Ia #RareDiseaseDay https://t.co/PwukvbhNaq
-
-
Mashup Score: 14Inspiring the Next Generation at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® - 1 year(s) ago
Dr. Shernan Holtan speaks with Dr. Bipin N. Savani on the impact of inspiring the next generation at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT® and…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
At #Tandem24, @sghmd spoke with @BipinSavani — 2024 recipient of the ASTCT Survivorship SIG Lifetime Achievement Award — on the impact of inspiring the next generation of #HCT & #celltherapy professionals. 🎤 Watch the interview on Nucleus: https://t.co/NgShHRiRfX https://t.co/bhoFrYZC3A
-
-
Mashup Score: 13Tandem 2024 Reflections: Late Effects and Survivorship Post BMT: Moving from Description to Prevention and Intervention - 1 year(s) ago
What stood out to you as the most crucial points discussed in the pre-transplant strategies to optimize the long-term health of the survivor session? The level of sarcopenia provides…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
Nucleus at #Tandem24: @GomezDLeonMD reflects on Late Effects and Survivorship Post #BMT: Moving from Description to Prevention and Intervention https://t.co/rbOqzfs4HA https://t.co/mQDkmbm1S1
-
-
Mashup Score: 6
In this latest episode of ASTCT Talks, Rachel Schollmeier and NMDP’s Samantha Watters host author Mike Niles, delving into the captivating history of the Anthony Nolan bone marrow transplant…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
In the latest episode of ASTCT Talks, hosts Rachel Schollmeier & @NMDP's Samantha Watters host author Mike Niles to uncover the fascinating history of bone marrow transplants. Learn about the challenges & advancements shaping the future. Listen now: https://t.co/9QyS26bDYP https://t.co/3GX4X2PHr8
-
-
Mashup Score: 0
Garderet L, Ouldjeriouat H, Bekadja M-A, et al. Low Non-Relapse Mortality and Good Haematological and Renal Responses After Autologous Haematopoietic Stem Cell Transplantation in Multiple Myeloma…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
The safety and efficacy of #autoHSCT has been called into question for multiple myeloma patients with renal dysfunction, but new findings support the standard of care in this patient subset. Read more on Nucleus: https://t.co/aGklqwLDDf #MMsm https://t.co/dIgAm1cv44
-
-
Mashup Score: 2
Potter V, Gras L, Koster L, et al. Sequential vs Myeloblative vs Reduced Intensity Conditioning for Patients With Myelodysplastic Syndromes With an Excess of Blasts at Time of Allogeneic…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
An analysis found outcomes after #alloHSCT in patients with higher-risk MDS are dictated primarily by baseline disease risk & individual characteristics, with choice of conditioning protocol having little impact. Read more on Nucleus: https://t.co/Bll46ppC0z https://t.co/2f7Kxw6Gvs
-
-
Mashup Score: 1Spatial Transcriptomics Reveals Distinct Tissue Niches Linked with Steroid Responsiveness in Acute Gastrointestinal GVHD - 1 year(s) ago
A study recently published in the journal Blood explored distinct spatial gene expression patterns in cellular compartments of lower gastrointestinal (GI) acute graft-versus-host disease (aGVHD)…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
A recent study in 'Blood' unveils unique gene patterns in GI aGVHD, highlighting the USP17L gene family's role in patient outcomes. Spatial transcriptomics offers insights into steroid response, aiding future therapies. Read more on Nucleus: https://t.co/kiiVdCeiub https://t.co/Vi881BYT68
-
-
Mashup Score: 0Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia - 1 year(s) ago
A phase 1 clinical trial, published in the journal Blood Advances, has found the optimal dosing schedule with a tolerable safety profile in patients with relapse/refractory (R/R) acute myeloid…
Source: nucleus.astct.orgCategories: General Medicine News, Onc News and JournalsTweet-
A phase 1 clinical trial has found optimal dosing schedule with a tolerable safety profile in patients with r/r acute myeloid leukemia. Read more on Nucleus: https://t.co/aAHxunRlcP https://t.co/zRxQapYKt3
-
During #Tandem24, Dr. @mustafahydermd from @theNCI presented results from a study on intermediate-dose PTCy in #BMT for older patients. Dr. Andrés Gómez De León details insights from the session on Nucleus: https://t.co/eUUHfB206o